

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

PROPOSED ON-MARKET SHARE PURCHASES APPROVED BY THE BOARD AND MANAGEMENT REFLECTING THE BOARD'S ASSESSMENT OF THE COMPANY'S INTRINSIC VALUE

This announcement is made by Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest development of the Group.

PROPOSED ON-MARKET SHARE PURCHASE

On June 11, 2026, the board (the “**Board**”) of directors of the Company (each a “**Director**”) approved the utilization of up to HK\$200 million to purchase the Company's ordinary shares (the “**Shares**”) on the open market. The proposed share purchase will be conducted by the trustee of the Company's 2021 restricted share unit scheme. The Board considers that the current trading price of the Shares does not reflect the intrinsic value and business prospects of the Company and that it presents a good opportunity to conduct the share purchase. The proposed share purchase demonstrates the confidence of the Board and the management in the business outlook and prospects of the Company and will in turn benefit the Company and create value for the shareholders. The proposed share purchase will be funded by the Company's existing available cash resources.

PROPOSED INCREASE IN SHAREHOLDINGS BY EXECUTIVE DIRECTORS AND SENIOR MANAGEMENT

The Board has also been informed that Dr. XIA Yu, the chairwoman, executive Director, president and chief executive officer of the Company, Dr. LI Baiyong, executive Director, Dr. WANG Zhongmin Maxwell, executive Director, Dr. ZHANG Peng, executive Director, and Dr. Bing C. WANG, the chief financial officer of the Company (collectively, the “**Relevant Directors and Senior Management**”) intend to increase their shareholdings in the Company by acquiring Shares on the open market in an aggregate amount of up to HK\$50 million, subject to compliance with the Listing Rules and other applicable laws and

regulations. As advised by the Relevant Directors and Senior Management, the proposed increase in their shareholders in the Company is based on their strong confidence in the Group's long-term investment value, robust research and development capabilities and ability to drive continued innovation, and will be funded by their own financial resources.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

Akeso, Inc.

Dr. XIA Yu

Chairwoman and executive Director

Hong Kong, June 11, 2026

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive Director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive Directors, Mr. XIE Ronggang as non-executive Director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive Directors.